Comparative Pharmacology
Head-to-head clinical analysis: CUPRIC CHLORIDE versus MULTIFUGE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CUPRIC CHLORIDE versus MULTIFUGE.
CUPRIC CHLORIDE vs MULTIFUGE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Copper is an essential trace element that serves as a cofactor for various enzymes, including cytochrome c oxidase (involved in mitochondrial respiration), superoxide dismutase (antioxidant defense), ceruloplasmin (iron metabolism), and lysyl oxidase (collagen cross-linking). It also participates in neurotransmitter synthesis and maintenance of vascular integrity.
Multifuge is a combination product containing an antihistamine and a decongestant. The antihistamine (chlorpheniramine) competitively antagonizes histamine H1 receptors, reducing allergic symptoms. The decongestant (pseudoephedrine) stimulates alpha-adrenergic receptors, causing vasoconstriction and reducing nasal congestion.
0.5 to 1.5 mg copper (0.14 to 0.42 mg/mL) IV daily as a supplement in TPN; typical adult dose: 0.4 mg copper/day IV.
IV: 10 mg/kg body weight as a single dose; repeated every 48 hours as needed.
None Documented
None Documented
Terminal half-life is approximately 12-24 hours; clinically relevant for dosing intervals in parenteral nutrition.
The terminal elimination half-life is 7-9 hours in adults with normal renal function. This may be prolonged (up to 20-30 hours) in patients with severe renal impairment (CrCl <30 mL/min), necessitating dose adjustment.
Primarily biliary (>80%) into feces; renal excretion accounts for <5% of total copper elimination under normal conditions.
Renal excretion of unchanged drug accounts for 60-70% of the administered dose, with the remainder undergoing hepatic metabolism to inactive metabolites that are excreted renally. Fecal elimination is minimal (<5%).
Category C
Category C
Mineral Supplement
Multivitamin/Mineral Supplement